Last reviewed · How we verify
Aclidinium bromide & formoterol fumarate
Aclidinium bromide and formoterol fumarate is a combination bronchodilator that blocks muscarinic receptors (anticholinergic) and activates beta-2 adrenergic receptors to relax airway smooth muscle and improve airflow.
Aclidinium bromide and formoterol fumarate is a combination bronchodilator that blocks muscarinic receptors (anticholinergic) and activates beta-2 adrenergic receptors to relax airway smooth muscle and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Aclidinium bromide & formoterol fumarate |
|---|---|
| Also known as | Duaklir Genuair |
| Sponsor | University of Dundee |
| Drug class | Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | M3 muscarinic receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Aclidinium is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors on airway smooth muscle, preventing bronchoconstriction. Formoterol is a long-acting beta-2 agonist (LABA) that stimulates beta-2 receptors to promote bronchodilation. Together, they provide dual bronchodilation through complementary mechanisms, improving lung function and reducing symptoms in obstructive airway disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Muscle cramps
Key clinical trials
- Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (PHASE3)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours. (PHASE4)
- Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease (PHASE4)
- The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: